C4 Therapeutics Inc
$ 3.73
2.47%
07 Aug - close price
- Market Cap 412,416,000 USD
- Current Price $ 3.73
- High / Low $ 3.75 / 3.65
- Stock P/E N/A
- Book Value 2.25
- EPS -1.10
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.20 %
- ROE -0.48 %
- 52 Week High 5.17
- 52 Week Low 1.69
About
C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$13.33
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CCCC
2026-08-03 14:11:23
C4 Therapeutics, Inc. is anticipated to report a loss of 23 cents per share, according to this earnings preview. The company's financial performance will be closely watched as it releases its upcoming earnings report.
2026-07-29 09:39:40
C4 Therapeutics Inc. (CCCC) is a clinical-stage biopharmaceutical company focusing on targeted protein degradation for difficult-to-treat diseases, particularly in oncology. Its stock is currently trading at $3.515, with a market cap of $260.72M. Analysts rate the stock as a "Buy" with a target price of $13.33, suggesting a significant upside potential despite recent market weakness.
2026-07-28 00:09:32
This article provides a financial health analysis of C4 Therapeutics Inc (CCCC), noting its stable financial status and low operational efficiency. The company's financial score is 6.09, placing it 288th out of 386 in the Biotechnology & Medical Research industry. It also highlights a recent quarterly revenue decrease of 15.00% year-over-year and a net profit decrease of 4.53% year-over-year.
2026-07-27 11:41:49
This article provides a valuation analysis for C4 Therapeutics Inc (CCCC), noting its current valuation score of 7.38 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio and mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
2026-07-27 04:40:57
This article details the shareholder structure of C4 Therapeutics Inc (CCCC), outlining its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdings for key investors. The data includes the proportion of shares held by various entities like Point72 Asset Management, Morgan Stanley, and RA Capital Management.
2026-07-26 11:40:57
This article provides an earnings forecast for C4 Therapeutics Inc (CCCC), highlighting its current earnings forecast score of 8.75 and an average price target of $10.00. Based on 7 analysts, the stock has a "Buy" rating with a significant upside potential of 265.30%. The report also includes expected revenue for the next quarter, past EPS performance, and future EPS expectations.
